NAT10 significantly contributes to an immunosuppressive tumor microenvironment and promoting tumor growth, by orchestrating critical pathways including immune cell recruitment, glycolysis enhancement, and PD-1 upregulation, thereby highlighting its pivotal role as a therapeutic target in cancer immunology. This evidence concerns the gene NAT10 and neoplasm.